Description:
The main objective of this trial is to assess the efficacy of onvansertib in combination with
nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of
participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma
(PDAC).
Title
- Brief Title: Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma
- Official Title: A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Clinical Trial IDs
- ORG STUDY ID:
CRDF-001
- NCT ID:
NCT04752696
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
Drug | Synonyms | Arms |
---|
Onvansertib | PCM-075 | Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU |
Nanoliposomal irinotecan | Onivyde, Nal-IRI | Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU |
Leucovorin | | Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU |
Fluorouracil | 5-FU | Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU |
Purpose
The main objective of this trial is to assess the efficacy of onvansertib in combination with
nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of
participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma
(PDAC).
Trial Arms
Name | Type | Description | Interventions |
---|
Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU | Experimental | The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU). | - Onvansertib
- Nanoliposomal irinotecan
- Leucovorin
- Fluorouracil
|
Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU | Experimental | Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU). | - Onvansertib
- Nanoliposomal irinotecan
- Leucovorin
- Fluorouracil
|
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed metastatic PDAC
- Has received 1 prior gemcitabine-based chemotherapy as first line therapy for
metastatic disease. Progression after completion of neoadjuvant or adjuvant therapy of
< 6 months in duration is considered 1 line of therapy for metastatic disease
- Has measurable disease according to Response Evaluation Criteria in Solid Tumors
Version 1.1 (RECIST v1.1), defined as at least 1 lesion that can be accurately
measured in at least 1 dimension (longest diameter to be recorded) as > 20 mm with
conventional techniques or as > 10 mm with spiral computed tomography (CT) scan
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Must be willing and able to undergo a tissue biopsy at screening; participants who, in
the opinion of the investigator, do not have tissue that is accessible for biopsy are
excepted from this criterion
- Women of childbearing potential: (defined as not post-menopausal for 12 months or no
previous surgical sterilization) and fertile men must agree to use adequate
contraception for the duration of study participation and for 4 months after the last
dose of nal-IRI. Male subjects must agree to refrain from sperm donation during the
study and for 4 months after the last dose of nal-IRI
- Ability to understand and the willingness to sign a written informed consent document.
Signed informed consent form must be obtained prior to initiation of study evaluations
and/or activities
- International Normalized Ratio (INR) < 1.5 unless on warfarin
- Participants with prior malignancy and who were treated with no evidence of active
disease more than 2 years from initial diagnosis are eligible
- Age ≥ 18 years
- Participants must have adequate organ and bone marrow function
Exclusion Criteria:
- Prior treatment with irinotecan, nal-IRI, or investigational PLK1 inhibitor
- Uncontrolled intercurrent illness including symptomatic congestive heart failure,
unstable angina pectoris, cardiac arrhythmia, and myocardial infarction within 3
months of initiation of therapy
- History of interstitial pneumonitis or interstitial lung disease
- Participants with microsatellite instability-high (MSI-H) tumors with no prior immune
checkpoint inhibitor exposure
- Pregnancy or lactation
- Participant has active and uncontrolled bacterial, viral, or fungal infection(s)
requiring systemic therapy
- QT interval with Fridericia's correction (QTcF) > 470 milliseconds. The QTcF should be
calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs).
In the case of potentially correctible causes of QT prolongation, (eg, medications,
hypokalemia), the triplicate ECG may be repeated once during Screening and that result
may be used to determine eligibility
- Planned concomitant use of medications known to prolong the QT/QTc interval
- Participant has undergone major surgical resection within 4 weeks prior to enrollment
- Participant received radiotherapy, surgery, chemotherapy, or an investigational
therapy within 2 weeks prior to study entry
- Participant has serious medical risk factors involving any of the major organ systems
such that the investigator considers it unsafe for the participant to receive an
experimental research drugs
- Serious psychiatric or medical conditions that could interfere with treatment
- Major bleeding in the last 4 weeks
- More than 1 prior chemotherapy regimen administered in the metastatic setting
- Unable or unwilling to swallow oral medication
- Use of strong CYP3A4 or UGT1A1 inhibitors or strong CYP3A4 inducers. Participants
currently receiving these agents who are able to switch to alternate therapy are not
excluded. Inhibitors should be stopped at least one week prior to the first dose of
protocol therapy and inducers should be stopped at least two weeks prior to initiation
of protocol therapy.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Overall Response Rate (ORR) |
Time Frame: | 6 months |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | |
Measure: | Duration of Response (DOR) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | |
Measure: | Overall Response Rate (ORR) in Participants Who Receive At Least 2 Treatment Cycles |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | Each cycle is 2 weeks. |
Measure: | Overall Survival (OS) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | |
Measure: | Disease Control Rate (DCR) |
Time Frame: | Up to 2 years |
Safety Issue: | |
Description: | |
Measure: | Reduction from Baseline in Serum CA19-9 Response |
Time Frame: | Baseline up to 2 years |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Cardiff Oncology |
Trial Keywords
- Pancreatic Ductal Adenocarcinoma
- Onvansertib
- Nanoliposomal irinotecan
- Leucovorin
- Fluorouracil
- PLK1
- PLK Inhibitor
Last Updated
May 14, 2021